While blood tests and MRIs remain the gold standard, a new frontier is emerging in the most accessible organ of the human body: the eye. Zilia is betting that the retina is the window not just to the soul, but to systemic health.

"Zilia isn't just selling equipment; they are selling a paradigm shift from reactive to predictive healthcare."

The digital footprint reveals a company in the early-to-mid growth phase. With 2,549 monthly visits and a global rank hovering around #6.6M, they are currently flying under the radar of the general public. However, the traffic composition is telling: 38% direct traffic indicates a strong word-of-mouth engine among clinicians and researchers who are actively seeking out Zilia by name.

• Proprietary OVR technology capturing ocular vascular data.
• Strong clinical leadership with diverse expertise in trials and product management.
• Early adoption of PWA technologies for accessible, platform-agnostic demos.